Overview

Efficacy and Safety Study of SUNPG1622

Status:
Terminated
Trial end date:
2019-09-03
Target enrollment:
Participant gender:
Summary
This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Pharma Global FZE
Sun Pharmaceutical Industries Limited